Papers by Charles M. Perou
Page 3 · newest first
- MRE11 liberates cGAS from nucleosome sequestration during tumorigenesisNature · 2024
- Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast CancerJAMA Network Open · 2023
- Gene signatures derived from transcriptomic-causal networks stratified colorectal cancer patients for effective targeted therapy2023
- Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trialsNature Communications · 2023
- Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancerJournal of Clinical Investigation · 2023
- Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer2023
- Tamoxifen Response at Single-Cell Resolution in Estrogen Receptor–Positive Primary Human Breast TumorsClinical Cancer Research · 2023
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic SubtypesJournal of Clinical Oncology · 2023
- Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)Clinical Cancer Research · 2023
- Distinct shared and compartment-enriched oncogenic networks drive primary versus metastatic breast cancerNature Communications · 2023
- Combination of Polymeric Micelle Formulation of TGFβ Receptor Inhibitors and Paclitaxel Produce Consistent Response Across Different Mouse Models of TNBC2023
- Gene-Expression Profiling to Decipher Breast Cancer Inter- and Intratumor HeterogeneityCold Spring Harbor Perspectives in Medicine · 2023
- Assessment of a Genomic Assay in Patients With ERBB2 -Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without PertuzumabJAMA Oncology · 2023
- Assessment of the HER2DX Assay in Patients With ERBB2 -Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and PertuzumabJAMA Oncology · 2023
- Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysisESMO Open · 2023
- Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrencenpj Breast Cancer · 2023
- Tamoxifen Response at Single Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors2023
- Data from Predicting Drug Responsiveness in Human Cancers Using Genetically Engineered Mice2023
- Data from Activation of Host Wound Responses in Breast Cancer Microenvironment2023
- Data from Activation of Host Wound Responses in Breast Cancer Microenvironment2023
- Supplementary Data from A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer2023
- Supplementary Data from A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer2023
- Data from Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study2023
- CCR Translation for This Article from Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study2023
- Data from Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer2023
- Data from Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell Types2023
- Data from Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell Types2023
- Data from Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast Cancer2023
- Data from A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer2023
- Data from A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer2023
- Supplemental Figure 3 from Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics2023
- Data from Fibroblast Growth Factor Receptor Signaling Dramatically Accelerates Tumorigenesis and Enhances Oncoprotein Translation in the Mouse Mammary Tumor Virus–Wnt-1 Mouse Model of Breast Cancer2023
- Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancerNature Communications · 2023
- Translating transcriptomic findings from cancer model systems to humans through joint dimension reductionCommunications Biology · 2023
- Landscape of Genetic Alterations Underlying Hallmark Signature Changes in Cancer RevealsTP53Aneuploidy–driven Metabolic ReprogrammingCancer Research Communications · 2023
- Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast CancerJAMA Oncology · 2023
- Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasisNature Cancer · 2022
- HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1JNCI Journal of the National Cancer Institute · 2022
- HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trialEBioMedicine · 2022
- RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast CancerCancer Epidemiology Biomarkers & Prevention · 2022
- Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancerBreast Cancer Research and Treatment · 2022
- High-Dose Paclitaxel and its Combination with CSF1R Inhibitor in Polymeric Micelles for Chemoimmunotherapy of Triple Negative Breast Cancer2022
- Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS studynpj Breast Cancer · 2022
- Multimodal Prediction of Breast Cancer Recurrence Assays and Risk of Recurrence2022
- Distinct Reproductive Risk Profiles for Intrinsic-Like Breast Cancer Subtypes: Pooled Analysis of Population-Based StudiesJNCI Journal of the National Cancer Institute · 2022
- Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer casesnpj Breast Cancer · 2022
- Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast CancerClinical Cancer Research · 2022
- Chemotherapy Coupled to Macrophage Inhibition Induces T-cell and B-cell Infiltration and Durable Regression in Triple-Negative Breast CancerCancer Research · 2022
- The Landscape of Immune Microenvironments in Racially Diverse Breast Cancer PatientsCancer Epidemiology Biomarkers & Prevention · 2022
- Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 womenScientific Reports · 2022